Are GSK’s legal troubles a threat to the firm’s survival?
Are GSK’s legal troubles a threat to the firm’s survival?
Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022
GlaxoSmithKline’s first-quarter figures show the company is on track for the year
GlaxoSmithKline’s first-quarter figures show the company is on track for the year
Latest results show that it's business as usual for pharmaceutical giant GlaxoSmithKline. Rupert Hargreaves casts his eyes over the numbers.
27 Apr 2022
Why GSK should turn down Unilever’s billions
Why GSK should turn down Unilever’s billions
Unilever has offered GSK £50bn for its consumer division. But while the cash will be a temptation, the deal is not in the interests of shareholders or…
22 Jan 2022
Unilever slides and GSK bounces after GSK knocks back £50bn bid
Unilever slides and GSK bounces after GSK knocks back £50bn bid
Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
17 Jan 2022
Shake-up at GSK won’t placate investors
Shake-up at GSK won’t placate investors
GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance…
2 Jul 2021
Activist investor Elliott takes takes a stake in Glaxo
Activist investor Elliott takes takes a stake in Glaxo
Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
22 Apr 2021
If you'd invested in: Renishaw and GlaxoSmithKline
If you'd invested in: Renishaw and GlaxoSmithKline
Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
2 Mar 2018
Subscribe to MoneyWeek and get your first six issues FREE
Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
GSK: on the mend?
GSK: on the mend?
Glaxo’s chief executive has stepped down after nine years at the top. Has he left the pharma giant in good health? Alex Rankine reports.
17 Feb 2017
A golden hello that says big companies aren't hearing us
A golden hello that says big companies aren't hearing us
When it comes to ridiculous executive pay, GlaxoSmithKline still doesn't get it, says Merryn Somerset Webb. But they're not the only ones.
29 Mar 2016
A fantastic investment weapon for private investors
A fantastic investment weapon for private investors
Ed Bowsher explains the 'secret weapon' that could help private investors generate excellent market-beating returns.
5 Aug 2014
If this corporate giant breaks up, shareholders should prosper
If this corporate giant breaks up, shareholders should prosper
The boss of pharmaceutical giant GSK has hinted the company could be split in two. That would be great news for shareholders, says Ed Bowsher.
29 Jul 2014
Don’t be tempted to buy banks – here are two better options
Don’t be tempted to buy banks – here are two better options
Bank shares might look cheap right now, but don't be tempted. There are better places to put your money, says Ed Bowsher. Here, he picks two stocks to…
27 Jun 2014
Shares in focus: A health check for Glaxo
Shares in focus: A health check for Glaxo
There are lots of things to like about GlaxoSmithKline, but the giant pharma is also facing some big challenges, says Phil Oakley. So, should you buy …
23 Jun 2014
My favourite stock in the Big Pharma sector
My favourite stock in the Big Pharma sector
Ed Bowsher explains what’s going on in the pharmaceuticals industry, and picks his favourite stock in the sector.
8 May 2014
Warren Buffett’s best advice – and two stocks to go with it
Warren Buffett’s best advice – and two stocks to go with it
Ed Bowsher explains the idea behind Warren Buffett’s '20-stock punchcard' investment theory, and highlights two companies that fit the bill nicely.
2 May 2014
Buy Big Pharma – the deal spree could be just beginning
Buy Big Pharma – the deal spree could be just beginning
With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains ho…
24 Apr 2014
The best place to go hunting for value in the UK stock market
The best place to go hunting for value in the UK stock market
You can still find value in some UK stocks, says Ed Bowsher. Here, he explains where you should be looking, and picks three of the best stocks to buy …
28 Mar 2014
Why now looks a good time to buy this blue-chip drug giant
Why now looks a good time to buy this blue-chip drug giant
GlaxoSmithKline has had a rotten time recently. But it’s still got plenty going for it. And now could prove a very good time to buy, says Ed Bowsher.
14 Nov 2013
China's crusade against pharma giants
China's crusade against pharma giants
China has taken Western pharmaceutical companies to task over alleged corruption in the country.
25 Jul 2013